Creative Planning
FENC icon

Creative Planning’s Fennec Pharmaceuticals FENC Stock Holding History

Creative Planning’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,037
Closed -$91K – 1994
2018
Q3 		$91K Buy
11,037
+1,000
+10% +$9.28K ﹤0.01% 1806
2018
Q2 		$105K Buy
+10,037
New +$119K ﹤0.01% 1765

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Creative Planning's FENC Position: Q4 2018 in Review

Creative Planning sold out of Fennec Pharmaceuticals (FENC) in Q4 2018, closing a stake of 11,037 shares — an estimated $91K sold.

Creative Planning first reported a position in FENC in Q2 2018 and held it in 2 quarters. The position peaked at $105K in Q2 2018. 47 funds tracked by Wall St. Rank hold FENC as of Q4 2018.

  • Creative Planning reported no remaining Fennec Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Creative Planning sold 11,037 Fennec Pharmaceuticals shares in Q4 2018, an estimated $91K.
  • Creative Planning first reported a position in Fennec Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Creative Planning's Fennec Pharmaceuticals position peaked at $105K in Q2 2018.
  • 47 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2018.

Based on Creative Planning's 13F filing for Q4 2018, filed 1 Feb 2019.